Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
DIA Global Annual Meet...DIA Global Annual Meeting
Not Confirmed
Not Confirmed
14-18 June, 2026
Discovery EuropeDiscovery Europe
Not Confirmed
Not Confirmed
15-16 June, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
DIA Global Annual Meet...DIA Global Annual Meeting
Industry Trade Show
Not Confirmed
14-18 June, 2026
Discovery EuropeDiscovery Europe
Industry Trade Show
Not Confirmed
15-16 June, 2026
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The financing aims to support AI in therapeutic discovery, focusing its platform on discovering and developing potent and selective antibody therapeutics for cancer and immune-related disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: Charles River Laboratories, Inc
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Charles River Laboratories, Inc
Deal Size : $18.0 million
Deal Type : Financing
Ability Biologics Closes $18 Million Seed Funding Extension for Immunomodulators
Details : The financing aims to support AI in therapeutic discovery, focusing its platform on discovering and developing potent and selective antibody therapeutics for cancer and immune-related disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 18, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE